Conotoxin peptide κ-CPTx-BTL01, preparation method therefor, and uses thereof

Patent metadata

Field	Value
Publication number	US-10501498-B2
Application number	US-201415539709-A
Country	US
Kind code	B2
Filing date	Dec 26, 2014
Priority date	Dec 26, 2014
Publication date	Dec 10, 2019
Grant date	Dec 10, 2019

Abstract

Provided is a new conotoxin peptide κ-CPTx-bt101. The conotoxin peptide κ-CPTx-bt101 has derivative polypeptide that has an amino acid sequence indicated by SEQ ID NO:1, or has derivative polypeptide that has an amino acid sequence indicated by SEQ ID NO:1 and that is formed after substitution, addition or deletion of one or more amino acids are performed and has original functions. Also provided is polynucleotide for coding the peptide, comprising a constructed body of the polynucleotide, an expression carrier and transformed cells. A peptide preparation method and uses in the treatment of diseases related to a calcium ion channel.

First claim

The invention claimed is:

1. A conotoxin peptide κ-CPTx-bt101, which is:
a polypeptide derived from polypeptide (a), which consists of the amino acid sequence as set forth in SEQ ID NO:1, by substitution of one or more amino acids therein and having the function of polypeptide (a), wherein the substitution of the one or more amino acids is selected from the group consisting of:
(i) substitution of the lysine at position 1 with arginine;
(ii) substitution of the threonine at position 4 with serine;
(iii) substitution of the valine at position 7 with leucine or isoleucine;
(iv) substitution of the glutamine at position 9 with asparagine;
(v) substitution of the valine at position 13 with leucine or isoleucine; and
(vi) substitution of the threonine at position 15 with serine.

2. A method to inhibiting a high-voltage activated calcium ion channel comprising administration, to a subject, an effective amount of the conotoxin peptide κ-CPTx-bt101 according to claim 1 .

3. A method for producing the conotoxin peptide κ-CPTx-bt101 according to claim 1 , which comprises:
(1) synthesizing the linear peptide of the conotoxin peptide κ-CPTx-bt101 according to its amino acid sequence by solid-phase chemical synthesis; and
(2) performing oxidative refolding of the linear peptide obtained in step (1) with glutathione method.

4. The method according to claim 3 , wherein the solid-phase chemical synthesis is fluorenylmethoxycarbonyl solid-phase chemical synthesis.

Assignees

• Bgi Shenzhen

Inventors

• Liu Jie
• Lin Zhilong
• Wen Bo
• Tong Ting
• Mo Fen
• Peng Chao
• Shi Qiong

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61K38/10

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• C12N15/63

  Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title

• C12N5/10

  Cells modified by introduction of foreign genetic material · CPC title

• C07K7/08

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title